Prenatal Malaria and Child Growth

What Did the New Malaria and Child Growth Study Find?

The BMJ Paediatrics Open study used data from the Ghana Randomized Air Pollution and Health Study, a pregnancy cohort that followed mother-child pairs through the child’s first year of life. Researchers identified prenatal malaria through placental histopathology and tracked early-child malaria through active health surveillance, clinical assessment and malaria testing when illness suggested infection.

Among 1,144 children with complete exposure and growth data, 250 had prenatal malaria exposure and 525 had malaria during early childhood. After adjustment for factors such as maternal characteristics, gestational age, insecticide-treated net use, preventive malaria treatment in pregnancy and household exposures, prenatal malaria remained associated with poorer length-for-age and head circumference growth trajectories. The study was observational, so it cannot prove causality, but its repeated measurements at birth, 3, 6, 9 and 12 months make the growth signal clinically important.

Why Can Malaria in Pregnancy Affect a Baby’s Growth?

Malaria in pregnancy is most often driven by Plasmodium falciparum in high-transmission settings, where infected red blood cells can accumulate in the placenta. That process is already known to be associated with maternal anemia, preterm birth and low birth weight, and the new cohort adds evidence that growth effects may continue across infancy.

Researchers highlighted plausible biological pathways, including placental inflammation and changes in placental blood-vessel development. These pathways matter because stunting is defined using WHO child growth standards as length or height-for-age more than two standard deviations below the reference median, and persistent early growth faltering is linked with higher infection risk, impaired development and long-term health vulnerability.

How Can Prevention Programs Use These Findings?

WHO identifies pregnant women and children under 5 as groups at high risk for severe malaria. Current prevention tools include insecticide-treated nets, prompt testing and treatment, intermittent preventive treatment in pregnancy where recommended, seasonal or perennial chemoprevention in eligible settings and WHO-recommended malaria vaccines for children in areas of moderate to high transmission.

For clinicians and public-health programs, the practical message is to connect antenatal malaria prevention with child growth monitoring. In non-endemic countries, the relevance is clearest for travel medicine: pregnant travelers and families with young children should seek pretravel advice, use destination-appropriate malaria prevention and treat fever after travel as an urgent medical symptom.